The short version of certificate of analysis fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with C-terminal amide |
| Average mass | Approximately 711.9 Da | Value derived from the formula |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and aqueous acetonitrile | Dissolution aided by acidic diluents |
| Common synonyms | Ipamorelin; NNC 26-0161 | Code name used in early reports |
Lyophilized ipamorelin powder is the form usually supplied for laboratory work. Kept dry, protected from light, and held at minus 20 degrees Celsius or below, it remains stable for extended periods, often measured in years. Once dissolved, the peptide degrades faster through hydrolysis, oxidation, and deamidation, so solutions are typically refrigerated and used within weeks. Repeated freeze-thaw cycles and exposure to alkaline conditions accelerate loss of the parent compound.
Reversed-phase high-performance liquid chromatography is the standard tool for assessing purity. Detection near 214 nanometers captures the peptide backbone, and the resulting chromatogram shows the main peak alongside related impurities. Electrospray ionization mass spectrometry confirms molecular mass and supports sequence verification. Common degradation products include oxidized residues, deamidated forms, and truncated fragments, each appearing as a distinct peak or shoulder in the trace.
Quality claims for research peptides vary widely across suppliers. A certificate of analysis should list purity by chromatography, the mass found by spectrometry, and the analytical conditions used. Independent testing at a third-party laboratory is a common way to check identity and purity, because documents alone cannot confirm what is inside a vial. Purity figures describe the proportion of the target peptide among detected species, and they say nothing about biological activity or sterility.
The Australian National University Act received royal assent on 1 August 1946. The act created the Australian National University (ANU), and gave the medical research institute the name "John Curtin School of Medical Research". H. C. "Nugget" Coombs, an economist and head of the Department of Post-War Reconstruction, accompanied the Prime Minister, Ben Chifley, on an official visit to the UK as his principal advisor. Coombs met with Florey in Oxford in May 1946. They agreed that the success of the new university would depend on the quality of faculty they could attract, and he wanted four eminent scholars to lead the four research schools: Florey for medicine, Mark Oliphant for physics, Keith Hancock for history, and Raymond William Firth for Pacific studies. Each received an official invitation in April 1947, and they were invited to come to Canberra for consultation in December 1947 and January 1948. They would constitute an academic advisory committee, for which they would be paid £250 (equivalent to A$20,242 in 2022) plus £200 (equivalent to A$16,193 in 2022) expenses per annum. Since they were all located in the UK, a London office of the university was opened to provide liaison. Florey never moved to Canberra, but he did accept the position of acting director of the John Curtin School of Medical Research for a five-year term commencing in May 1948 in order to establish it. Brian Lewis had been appointed university architect, but Florey hired Stephen Welsh, the professor of architecture at Sheffield University.
Another use for affinity chromatography is the purification of specific proteins using a gel matrix that is unique to a specific protein. For example, the purification of E. coli β-galactosidase is accomplished by affinity chromatography using p-aminobenyl-1-thio-β-D-galactopyranosyl agarose as the affinity matrix. p-aminobenyl-1-thio-β-D-galactopyranosyl agarose is used as the affinity matrix because it contains a galactopyranosyl group, which serves as a good substrate analog for E. coli β-Galactosidase. This property allows the enzyme to bind to the stationary phase of the affinity matrix and β-Galactosidase is eluted by adding increasing concentrations of salt to the column. Alkaline phosphatase from E. coli can be purified using a DEAE-Cellulose matrix. A. phosphatase has a slight negative charge, allowing it to weakly bind to the positively charged amine groups in the matrix. The enzyme can then be eluted out by adding buffer with higher salt concentrations.
Np(III) or Np3+ exists as hydrated complexes in acidic solutions, Np(H2O)3+n. It is a dark blue-purple and is analogous to its lighter congener, the pink rare-earth ion Pm3+. In the presence of oxygen, it is quickly oxidized to Np(IV) unless strong reducing agents are also present. Nevertheless, it is the second-least easily hydrolyzed neptunium ion in water, forming the NpOH2+ ion. Np3+ is the predominant neptunium ion in solutions of pH 4–5.
Sources: en.wikipedia.org
Internal coenzyme/cofactor photocatalyst External photocatalyst Certain common hydrogen atom transfer (HAT) cofactors (NADPH and Flavin) can operate as single electron transfer (SET) reagents. Although these species are capable of HAT without irradiation, their redox potentials are enhance by nearly 2.0 V upon visible light irradiation. When paired with their respective enzymes (typically ene-reductases) This phenomenon has been utilized by chemists to develop enantioselective reduction methodologies. For example medium sized lactams can be synthesized in the chiral environment of an ene-reductase through a reductive, baldwin favored, radical cyclization terminated by enantioselective HAT from NADPH. The second category of photoredox enabled biocatalytic reactions use an external photocatalyst (PC). Many types of PCs with a large range of redox potentials can be utilized, allowing for greater tunability of reactive compared to using a cofactor. Rose bengal, and external PC, was utilized in tandem with an oxidoreductase to enantioselectively deacylate medium sized alpha-acyl-ketones. Using an external PC has some downsides. For example, external PCs typically complicate reaction design because the PC may react with both the bound and unbound substrate. If a reaction occurs between the unbound substrate and the PC, enantioselectivity is lost and other side reactions may occur.
Using purified proteins on substrates including artificial lipid bilayers and flow-based adhesion assays, his lab discovered the first heterophilic (like-unlike) receptor–counter-receptor adhesion pairs in all of cell biology, including CD2–LFA-3 and LFA-1–ICAM. The LFA-1–ICAM interaction required Mg2+, and explained the Mg2+-dependence of cell adhesion in antigen recognition. Subsequently, Springer structurally resolved the LFA-1–ICAM-1 interaction, with Mg2+ at the ligand-binding interface.
In 2005, it launched an original property of its creation, Brothers in Arms, with the release of Brothers in Arms: Road to Hill 30 on the Xbox, PC and PlayStation 2. Later that year a sequel, Brothers in Arms: Earned in Blood, was launched. In 2008, Brothers in Arms: Hell's Highway was released. 2007 brought announcements of new projects based on licensed film intellectual properties, including the crime drama Heat and the science-fiction classic Aliens. In the September 2007 issue of Game Informer, Pitchford stated that development on the Heat game had not yet begun, as the planned development partner for the project had gone under. This was followed by an announcement by Sega that it would be helming a new version of rhythm game Samba de Amigo for the Wii, a departure from its signature first-person shooter titles.
Sources: en.wikipedia.org
=== Laboratory automation development === Markin's interest in laboratory automation, blending clinical processes with information technology, began during his graduate studies, which focused on graph theory. By 1989, he developed a prototype system that would later allow "plug-and-play" integration of automation systems and clinical analyzers for managing and testing of patient specimens. His approach was to build an automated transport system which would allow various testing processes using commercial, off-the-shelf testing and collection systems. He didn't design the instruments, but sought an automated system to manage the testing processes, leading to increased efficiency, improved reporting and lower laboratory costs. He founded LAB-InterLink in 1993, and commercialized a system to manage clinical specimens using an automated transportation system and specimen processing devices (i.e. decapping devices, recapping devices, instrument or analyzer interfaces, etc.) for laboratory testing and processing. For example, the specimen would be separated using a centrifuge; the specimen container would be uncapped; the specimen would be tested as ordered by the physician; the container would be recapped; and the specimen would be stored in the event further testing is needed. Test results were provided to the physician or provider as part of the software management system. LAB-InterLink sold automation systems in North America and internationally, and offices were set up in the United States, Canada and Israel. In 2004, the U.S.
In the Pilbara region of Western Australia, compelling evidence of early life was found in pyrite-bearing sandstone in a fossilized beach, with rounded tubular cells that oxidized sulfur by photosynthesis in the absence of oxygen. Carbon isotope ratios on graphite inclusions from the Jack Hills zircons suggest that life could have existed on Earth from 4.1 Gya. A 2024 study inferred LUCA's age as around 4.2 Gya (4.09–4.33 Gya) by analysing pre-LUCA gene duplicates, with calibration from fossil micro-organisms, much sooner after the origin of life than previously thought. The Pilbara region of Western Australia contains the Dresser Formation with rocks 3.48 Gya, including layered structures called stromatolites. Their modern counterparts are created by photosynthetic micro-organisms including cyanobacteria. These lie within undeformed hydrothermal-sedimentary strata; their texture indicates a biogenic origin. Parts of the Dresser formation preserve hot springs on land, but other regions seem to have been shallow seas. A molecular clock analysis suggests the LUCA emerged prior to 3.9 Gya.
Afghanistan was formerly the primary producer of the drug. Having regularly producing 70 percent of the world's opium, Afghanistan decreased production to 74 tons per year under a ban by the Taliban in 2000, a move which cut production by 94 percent. A year later, after American and British troops invaded Afghanistan, removed the Taliban and installed the interim government, the land under cultivation leapt back to 285 square miles (740 km2), with Afghanistan supplanting Burma to become the world's largest opium producer once more. Opium production increased rapidly in Afghanistan from that point, reaching an all-time high in 2006. According to DEA statistics, Afghanistan's production of oven-dried opium increased to 1,278 tons in 2002, more than doubled by 2003, and nearly doubled again during 2004. In late 2004, the U.S. government estimated that 206,000 hectares were under poppy cultivation, 4.5 percent of the country's total cropland, and produced 4,200 metric tons of opium, 76 percent of the world's supply, yielding 60 percent of Afghanistan's gross domestic product. In 2006, the UN Office on Drugs and Crime estimated production to have risen 59 percent to 165,000 hectares (407,000 acres) in cultivation, yielding 6,100 tons of opium, 82 percent of the world's supply. The value of the resulting heroin was estimated at US$3.5 billion, of which Afghan farmers were estimated to have received US$700 million in revenue. For farmers, the crop can be up to ten times more profitable than wheat. The price of opium is around US$138 per kilo.
Sources: en.wikipedia.org
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.
It has not received marketing approval as a medicine in the United States or the European Union. Supplied material is generally described and handled as a research chemical. Regulatory treatment varies by jurisdiction, and some countries restrict growth hormone secretagogues under sports or medicines legislation.
Earlier secretagogues were associated with broader hormonal responses, including measurable changes in cortisol and prolactin. Reports on this peptide describe a narrower profile in which growth hormone release is the most prominent effect. The observation is influential because it shapes how the compound is compared with other members of the same receptor family.
It is a synthetic pentapeptide in the growth hormone secretagogue family and acts as an agonist at the ghrelin receptor. It is handled as a laboratory research compound rather than a naturally occurring hormone.